t the conclusion of the activity, participants should be able to

• Discuss FDA or current events that may impact important pipeline drug release dates.
• Identify high impact brand and generic drugs newly approved/ upcoming pipeline.
• Describe the mechanism of action and expected indications of promising therapy.
• Identify indications, contraindications, and potential drug interactions of the new medications.
• Outline key Pharmacy and Therapeutics Committee considerations of pipeline brands and generics.